For the over 1 million Americans who survive severe traumatic brain injuries each year, the road to recovery is often long and challenging.
FDA rejects Coherus’ reworked Neulasta biosimilar due to third-party inspections
The FDA has rejected Coherus BioSciences’ new presentation for its Udenyca (pegfilgrastim-cbqv) biosimilar due to an inspection at one of its contractors. Coherus said the